Azadeh Nasrazadani, MD, PhD
Articles by Azadeh Nasrazadani, MD, PhD
TROPION-Breast02: First-Line Datopotamab Deruxtecan in Metastatic TNBC
ByWilliam J Gradishar, MD, FASCO, FACP,Francisco J. Esteva, MD, PhD,Gregory Vidal, MD, PhD,Azadeh Nasrazadani, MD, PhD,Yuan Yuan, MD, PhD,Mohammadbagher Ziari, MD,Anastasia Martynova, MD In this segment, the panel reviews the phase 3 TROPION-Breast02 trial evaluating first-line datopotamab deruxtecan (Dato-DXd) versus investigator’s choice of chemotherapy in patients with locally advanced, inoperable, or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option.
Introduction to the Face-Off and Metastatic TNBC Treatment Landscape
ByWilliam J Gradishar, MD, FASCO, FACP,Francisco J. Esteva, MD, PhD,Gregory Vidal, MD, PhD,Azadeh Nasrazadani, MD, PhD,Yuan Yuan, MD, PhD,Mohammadbagher Ziari, MD,Anastasia Martynova, MD In this introductory segment, Dr. William J. Gradishar of Northwestern University Feinberg School of Medicine welcomes viewers to Cancer Network’s Face-Off and introduces the evolving treatment landscape in metastatic triple-negative breast cancer (TNBC).
